News & Events


New Year’s Message

New Year’s Message
10 January 2017

Happy New Year to all of our valued clients and colleagues!

As we move into 2017, I wanted to take a moment to share my thoughts regarding our continued vision for Synteract. As you all know, our mission to bring a better future for patients through drug and device development is carried out in a challenging, dynamic and highly competitive environment.  Clinical trials continue to grow more complex, with continued pressure for enhanced efficiencies, shorter timelines, and access to patients internationally, while still ensuring the integrity and quality of deliverables. Here at Synteract we address these real world demands in our day to day operations and in our plans for growth, with continued intent to provide flexible, top-notch services to our customers. In this super-charged industry, we have the experience and expertise to guide our small to mid-sized and emerging drug and device clients in planning and implementing the programs you need.

Especially at the start of a new year, we believe it is good for us as a company to examine ourselves and honestly assess where we’re going and what it will take to get there. So, to that end, driven by our goal for even better service delivery, we have been working with consultants from Deloitte over the past six months to re-assess our current capabilities, both identifying areas of strength and noting areas where we may need to augment our processes, tools and/or human capital to stay ahead of evolving customer demands.

We have created a cross-functional service delivery group whose basic responsibility is to focus on optimizing service delivery to clients, assessing processes and tools for the teams to ensure the best customer support possible. We are continuing to upgrade our operational platforms for scale, efficiency and improved results, looking at three main areas of focus:

  • Study start-up from feasibility to site activation
  • Monitoring
  • Trial master file

We know that as trials become increasingly more expensive to do, site identification and study start-up become ever more important; everyone is looking for shortened start-up times, even though the trials are more complex than ever before.

We are continuing to augment our team of experienced, global talent in 2017 as we did in 2016, finding professionals with the experience and international acumen that clients need from us to support their ever larger, more complicated trials. We will continue to let you know about these talent additions as they come on board.

Finally, our “Shared Work, Shared Vision” philosophy has been the way we do business for many years, and remains so.  It means that you can count on our continued transparency and collaboration, as well as our scientific, regulatory and operational expertise. All of us, from your direct project team members through executive management,  have the same vision as you, with a goal to deliver what we have promised by meeting or exceeding your expectations. We know that our ability to communicate openly – sharing plans, milestones, and concerns – will build the strong partnership you need so that together we can proactively address any challenges that come along. As always, we are open to your feedback and suggestions and look forward to our continued collaboration in 2017.

Wishing you all a happy, healthy and prosperous new year!

Wendel Barr,  CEO


Contact Synteract

Tell us how to stay in touch with you: